Loading quotes...
Forecast
The analysts' average price target is €6.97 (+128.52%). The median is €6.97 (+128.52%).
| Buy |
1 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
SeaStar Medical sponsors KidneyBee Summit and webinar on QUELIMMUNE for children with acute kidney failure
SeaStar Medical announces sponsorship support for the KidneyBee Summit 2026 at Children’s Hospital Colorado and a continuing-education webinar on August 11, 2026. The webinar covers the QUELIMMUNE therapy (SCD-PED) for treating critically ill children with acute kidney failure and sepsis; speakers include Dr. Stuart Goldstein, Dr. Stephen Gorga and Dr. Kevin Chung. QUELIMMUNE was approved in February 2024 via a Humanitarian Device Exemption; studies and registry data showed survival rates of about 71–77% in treated pediatric patients. The stock (NASDAQ:ICU) has risen nearly 100% year-to-date and trades at $4.79 with a market capitalization of $19.3 million. » More on de.investing.com
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 538.87k | 87.91% |
| Gross profit | 491.55k | 86.29% |
| Net profit | -3.27m | 92.42% |
| EBITDA | -3.25m | 92.15% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €7.46m |
Number of shares | 2.84m |
52-week high/low | €10.89 - €1.80 |
| Dividends | No |
Beta | -1.03 |
P/E ratio | -0.77 |
PEG ratio | 0.00 |
P/B ratio | 2.87 |
P/S ratio | 5.00 |
Company profile
| Name | SeaStar Medical Holding Corp Ordinary Shares |
| CEO | Eric Schlorff |
| Employees | 18 |
